Since its U.S. launch in January 2004, Restylane quickly has become the market leader among cosmetic dermal fillers. In addition to its long-standing safety profile in the clinical and real-world settings, Restylane also offers physicians and patients long-lasting results. In fact, of all the FDA-approved fillers available today, Restylane is the only one with clinical data supporting its efficacy for as long as six months.
This year, Restylane was one of only eight products to receive the coveted Best of Beauty Breakthrough award. Breakthrough winners are selected by the editors of Allure magazine. A complete list of award recipients appears in the October issue of Allure, which is currently available on newsstands.
Restylane is the first and only dermal filler made of crystal-clear gel called NASHA(TM) (Non-Animal Stabilized Hyaluronic Acid). Restylane uses a dual mechanism of action to correct wrinkles and folds. Upon being injected beneath the skin's surface, the NASHA gel adds natural volume and lift to smooth wrinkles and folds. The NASHA gel integrates into dermal tissue, then attracts and binds to water molecules to help maintain volume. Restylane is gradually degraded by the body's own mechanism and disappears without any residue. Results can be seen immediately following treatment and last six months, or even longer. Restylane does not require any allergy or skin test prior to injection. As with any dermal filler, reported side effects include temporary redness and swelling at the injection site. These effects usually resolve within two days.
Restylane is a prescribed medical product, so please speak with your dermatologist or cosmetic surgeon to see if it is right for you. For more information on Restylane, including complete product information, log on to www.restylaneusa.com
Medicis Aesthetics Inc., the company that is marketing and selling Restylane in the U.S., is a wholly-owned subsidiary of Medicis Pharmaceutical Corporation, a leading independent specialty pharmaceutical company in the United States focusing primarily on the treatment of aesthetic, dermatological, and podiatric conditions. Medicis Pharmaceutical Corporation has leading branded prescription products in a number of therapeutic categories, including acne, eczema, fungal infections, psoriasis, rosacea, seborrheic dermatitis and skin and skin-structure infections. The Company's products have earned wide acceptance by both physicians and patients due to their clinical effectiveness, high quality and cosmetic elegance.
NOTE: RESTYLANE(R) is a registered trademark of HA North American Sales AB, a subsidiary of Medicis Pharmaceutical Corporation.